Immune cells take on nerve tumors in early trial
NCT ID NCT04085159
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This study tests a personalized cell therapy using a patient's own immune cells, modified to target tumor-associated antigens, along with a dendritic cell vaccine. The goal is to see if this approach is safe for people with neurofibromatosis or schwannomatosis. Up to 100 participants aged 1 year and older with progressing tumors will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Neurosurgery, Shenzhen Hospital, Southern Medical University
RECRUITINGShenzhen, Guangdong, 518100, China
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Antigen-specific T cells (CAR-T/CTL) and dendritic cell vaccine (DCvac)
What this could lead to
If successful, this could point toward a new treatment option to control tumors in people with neurofibromatosis or schwannomatosis.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. There may be side effects from the cell therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.